Helix Energy Solutions Gr... (HLX)

Helix Energy Solutions reported mixed first quarter results, with lower-than-expected revenues offset by higher profitability. Recent events, including OPEC+ production increases and U.S. tariffs, hav...

Helix Energy Solutions Group, Inc. (NYSE:HLX ) Q1 2025 Results Conference Call April 24, 2025 10:00 AM ET Company Participants Brent Arriaga - Vice President, Finance and Accounting Owen Kratz - Chief...

Helix Energy (HLX) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.03 per share a year ago.

HOUSTON--(BUSINESS WIRE)--Helix Energy Solutions Group, Inc. ("Helix") (NYSE: HLX) reported net income of $3.1 million, or $0.02 per diluted share, for the first quarter 2025 compared to net income of...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

Unlock your portfolio value with value stocks like Alibaba, Fresenius Medical, Helix Energy and Heritage Insurance. All these stocks boast high earnings yield.

HOUSTON--(BUSINESS WIRE)--Helix Energy Solutions Group, Inc. (NYSE: HLX) will issue a press release reporting its first quarter 2025 results on Wednesday, April 23, 2025, after the close of business. ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Henlius and Organon announced the European Medicines Agency validates filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11.

Helix Energy Solutions reported increased revenues, profits, net income, and free cash flow for Q4 2025. The company expects stronger performance through 2025 with some sector risks. The stock price r...